Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Lists
Only you see this
Abstract
Combined apatinib and camrelizumab showed encouraging antitumor activity and acceptable toxicity in chemotherapy-pretreated patients with advanced nonsquamous NSCLC. Patients with STK11/KEAP1 mutation might derive more benefits from this combination. We will validate these results in an ongoing phase III trial (NCT04203485).
BibTeX
@inproceedings{zhou2021efficacy,
author = {Caicun Zhou and Yina Wang and Jun Zhao and Gongyan Chen and Zhihua Liu and Kangsheng Gu and Meijuan Huang and Jianxing He and Jianhua Chen and Zhiyong Ma and Jifeng Feng and Jianhua Shi and Xinmin Yu and Ying Cheng and Yu Yao and Yuan Chen and Renhua Guo and Xiaoyan Lin and Zhehai Wang and Guanghui Gao and Quanren Wang and Weixia Li and Xinfeng Yang and Lihong Wu and Jun Zhang and Shengxiang Ren},
title = {{Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy}},
booktitle = {Clinical},
year = {2021},
doi = {10.1158/1078-0432.ccr-20-3136},
}Loading related content...